SUMMARY The effects of transgenically encoded human and mouse IL-18 on T cell proliferation and its application in boosting chimeric antigen receptor (CAR) T cells are presented. Robust enhancement of proliferation of IL-18-secreting human T cells occurred in a xenograft model, and this was dependent on TCR and IL-18R signaling. IL-18 augmented IFN-γ secretion and proliferation of T cells activated by the endogenous TCR. TCR-deficient, human IL-18-expressing CD19 CAR T cells exhibited enhanced proliferation and antitumor activity in the xenograft model. Antigen-propelled activation of cytokine helper ensemble (APACHE) CAR T cells displayed inducible expression of IL-18 and enhanced antitumor immunity. In an intact mouse tumor model, CD19-IL-18 CAR T cells induced deeper B cell aplasia, significantly enhanced CAR T cell proliferation, and effectively augmented antitumor effects in mice with B16F10 melanoma. These findings point to a strategy to develop universal CAR T cells for patients with solid tumors.
Proteins play a crucial role in life, taking part in all vital processes in the body. Intracellular protein delivery holds enormous promise for biological and medical applications, including cancer therapy, vaccination, regenerative medicine, treatment for loss-of-function genetic diseases and imaging. Engineering vehicles for escorting therapeutic proteins into specific cells in a controlled release fashion has thus generated considerable interest. The development of such therapeutics to selectively target tumor has also been a major research focus in cancer nanotechnology. A novel strategy using polymeric redox-responsive nanocapsules for intracellular protein delivery is described, in which through in situ interfacial polymerization, the target therapeutic protein is noncovalently encapsulated into a biocompatible polymeric shell interconnected by disulfide-containing crosslinkers. The dissociation of the polymeric shell under reducing conditions and the subsequent release of protein were confirmed using cell-free assays in the presence of glutathione. Several therapeutic proteins with different properties, both cytosolic and nuclear, were successfully delivered using the platform. The nanocapsules were demonstrated to be efficiently internalized into mammalian cells through interactions between charge or targeting ligand, iii and to release the protein in the reducing cytosol in active forms. Using such redoxresponsive nanocapsule as a vehicle, pro-apoptotic protein caspase 3 was delivered to induce apoptosis in a variety of human cancer cell lines, including HeLa, MCF-7 and U-87 MG.Tumor-selective killer apoptin was delivered into different breast cancer cell lines as well, which led to rapid resurrection of apoptosis in breast cancer cell lines and shrinkage of xenograft mice models. Tumor suppressor p53 protein, the most commonly mutated protein, was also delivered selectively into tumor cells for apoptosis induction, through targeted redox-responsive nanocapsules. The delivery methodology is general, effective and nontoxic towards healthy cells. This work facilitate the development of new tools for tumorgenesis and drug resistance studies, as well as expanding current therapeutic target pool to many other tumor suppressor proteins for cancer treatment.iv The Dissertation of Muxun Zhao is approved.
Target proteins can be functionally encapsulated using a cocoon-like polymeric nanocapsule formed by interfacial polymerization. The nanocapsule is cross-linked by peptides that can be proteolyzed by proteases upon which the protein cargo is released. The protease-mediated degradation process can be controlled in a spatiotemporal fashion through modification of the peptide cross-linker with photolabile moieties. We demonstrate the utility of this approach through the cytoplasmic delivery of the apoptosis inducing caspase-3 to cancer cells.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.